{"id":"W4251849256","doi":"10.1200/jco.2021.39.6_suppl.tps187","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Enzalutamide; Prostate cancer; Clinical endpoint; Metastatic breast cancer; Oncology; Internal medicine; Nuclear medicine; Cancer; Clinical trial; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004151269,0.002575037,0.003489466,0.0004190529,0.0008065377,0.001646622,0.001516224,0.002239838,0.007530847],"category_scores_gemma":[0.002743453,0.001268098,0.00167921,0.000617045,0.00236968,0.001689627,0.0005204756,0.003743327,0.001702186],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001355662,"about_ca_system_score_gemma":0.002757515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001416492,"about_ca_topic_score_gemma":0.0025188,"domain_scores_codex":[0.9983627,0.0008958849,0.00009309543,0.0003124595,0.0001130139,0.000222805],"domain_scores_gemma":[0.9977486,0.0004385302,0.0005202348,0.0002327506,0.0001794627,0.0008804087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9760464,0.01380969,0.0007822766,0.0001847565,0.0004357416,0.00003136809,0.00005025606,0.0001632103,0.003282342,0.00005658584,0.000491956,0.00466552],"study_design_scores_gemma":[0.8905866,0.1064323,0.00166448,0.000009605573,0.0002456735,0.00002698496,0.00001858977,0.0002153521,0.0003240971,0.00006316089,0.0004019514,0.00001113657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839702,0.001708091,0.0009879855,0.0005568119,0.0004539005,0.00922176,0.001350812,0.0001427308,0.001607595],"genre_scores_gemma":[0.9748631,0.001477206,0.003011038,0.001489551,0.0007840646,0.01251054,0.002076385,0.00006386962,0.003724293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007530847,"threshold_uncertainty_score":0.02519315,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06995440332410377,"score_gpt":0.4711628165296015,"score_spread":0.4012084132054977,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}